Welcome to our dedicated page for Zoetis SEC filings (Ticker: ZTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
As the world鈥檚 largest dedicated animal-health company, Zoetis divides its revenue between companion-animal vaccines and production-livestock therapeutics. That split makes every Zoetis 10-K a deep dive into pet-care demand, feedlot economics, and veterinary R&D pipelines鈥攄etails investors can鈥檛 afford to miss.
Stock Titan gathers every Zoetis SEC filing in one place and layers in AI-powered summaries that turn dense disclosures into plain-English insights. Whether you need the Zoetis quarterly earnings report 10-Q filing to track segment margins, crave Zoetis Form 4 insider transactions real-time, or want the Zoetis proxy statement executive compensation broken down, our platform delivers. We link each form to the question it answers: 8-K material events explained when supply constraints hit, the Zoetis annual report 10-K simplified for vaccine pipeline updates, and Zoetis insider trading Form 4 transactions pushed to you immediately.
Here鈥檚 how professionals use the page:
- Track Zoetis executive stock transactions Form 4 the moment they hit EDGAR.
- Analyze quarter-over-quarter trends with our Zoetis earnings report filing analysis.
- Quickly surface risk-factor changes by understanding Zoetis SEC documents with AI.
- Set alerts for Zoetis 8-K material events explained such as FDA approvals or recalls.
Every document is fetched from EDGAR the instant it posts, then distilled by expert models so you can move from data to decision without delay. Our dashboard offers Zoetis SEC filings explained simply, giving veterinarians, portfolio managers, and ag-sector analysts the regulatory signals that matter鈥攎inus the page-count fatigue.
Zoetis Inc. (ZTS) filed an automatic shelf registration statement on Form S-3 as a well-known seasoned issuer, enabling the company and future selling securityholders to issue an indeterminate amount of securities, including debt, common and preferred stock, warrants, depositary shares, purchase contracts/units, guarantees and hybrid instruments.
Each issuance will be detailed in a later prospectus supplement; no specific size, price or timing is disclosed in this filing. Net proceeds, when and if raised, may fund general corporate purposes such as working capital, capital expenditures, acquisitions and debt refinancing.
The prospectus summarises indenture terms鈥攑ari-passu ranking, optional redemption, covenants limiting certain liens and sale-leasebacks, standard events of default and defeasance options. The company re-confirms its NYSE listing (symbol 鈥淶TS鈥�) and notes 443.9 million common shares outstanding (authorised: 6 billion).
Risk factors are incorporated by reference and cover competitive pressures, supply-chain disruption, economic conditions, regulation, FX volatility and substantial indebtedness. The filing involves no immediate security issuance; it simply preserves capital-raising flexibility.
Zoetis (ZTS) Q2-25 10-Q highlights:
- Revenue rose 4.2% YoY to $2.46 bn; H1-25 up 2.8% to $4.68 bn.
- Net income climbed 15.1% YoY to $718 m; diluted EPS $1.61 vs $1.37. H1 EPS $3.02 (+13%).
- Gross margin improved to 73.6% (cost of sales down 2.8% despite higher volume).
- Operating expenses were mixed: SG&A +6.2%, R&D flat, amortization -6.3%. Restructuring & A&D costs fell to $30 m from $42 m.
- Effective tax rate 20.4% vs 20.0%.
- Segment trends: Companion animal +8.4% to $1.79 bn; Livestock -8.1% to $638 m. Strongest products: Parasiticides (+12%), Vaccines (+13%), Dermatology (+11%). Anti-infectives -17%.
- Cash $1.44 bn (-$552 m YTD) after $781 m buybacks and $447 m dividends. Debt unchanged at $6.65 bn; net debt up.
- Treasury shares outstanding 57.9 m; $4.9 bn remains on $6 bn repurchase authorization.
- Inventory rose 5.8% YoY to $2.44 bn; restructuring accrual $20 m.
- IRS audit could add up to $450 m tax liability; uncertain timing.
Overall, Zoetis delivered double-digit EPS growth driven by companion animal strength and margin expansion, while livestock softness, rising inventories and tax/audit uncertainties warrant monitoring.
FAQ
What is the current stock price of Zoetis (ZTS)?
What is the market cap of Zoetis (ZTS)?
